Phase II study of ifosfamide, carboplatin, and etoposide in patients with advanced non-small cell lung cancer

This study was to define the efficacy of ifosfamide, mesna, carboplatin, and etoposide (ICE) in patients with metastatic non-small cell lung cancer (NSCLC). From September 1990 to October 1991, 33 patients were treated with ifosfamide/mesna 1.25 g/m 2 /day and etoposide 80 mg/m 2 /day intravenously from days 1 to 3, and carboplatin 300 mg/m 2 on day I every 4 weeks. There were 20 male patients and 13 females. The median age was 65 (range: 38-79). Seventeen patients had a performance status (PS) of 0 or 1, and 16 had a PS of 2 or 3. All had measurable diseases. Nine had initial treatment for localized disease with concurrent radiation, 5-fluorouracil, and interferon-α 2b and four had radiation only. None had received chemotherapy for metastatic disease